Metformin for neurocognitive dysfunction in schizophrenia: a systematic review
BackgroundThe efficacy and safety of metformin for addressing neurocognitive dysfunction in schizophrenia remain inconclusive. This systematic review evaluates the evidence from randomized controlled trials (RCTs) on the effects of metformin on neurocognitive function in patients with schizophrenia....
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1540153/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593527661395968 |
|---|---|
| author | Zhen-Juan Qin Zhan-Ming Shi Li-Juan Li Xin Wei Hui-Lin Hu Wei Wei Zhi-Yuan Xie Hang-Xi Ji Yu-Hua Wei Wei Zheng Wei Zheng |
| author_facet | Zhen-Juan Qin Zhan-Ming Shi Li-Juan Li Xin Wei Hui-Lin Hu Wei Wei Zhi-Yuan Xie Hang-Xi Ji Yu-Hua Wei Wei Zheng Wei Zheng |
| author_sort | Zhen-Juan Qin |
| collection | DOAJ |
| description | BackgroundThe efficacy and safety of metformin for addressing neurocognitive dysfunction in schizophrenia remain inconclusive. This systematic review evaluates the evidence from randomized controlled trials (RCTs) on the effects of metformin on neurocognitive function in patients with schizophrenia.MethodsA comprehensive search of Chinese databases (WanFang, Chinese Journal Net) and English databases (PubMed, EMBASE, PsycINFO, and Cochrane Library) was conducted to identify RCTs assessing metformin’s impact on neurocognitive outcomes in schizophrenia.ResultsFour RCTs involving 271 patients with schizophrenia were included. Three RCTs (75%) demonstrated significant improvements in neurocognitive function with metformin compared to controls, as assessed by the MATRICS Consensus Cognitive Battery, Repeatable Battery for the Assessment of Neuropsychological Status, and Mini-Mental State Examination, but not the Brief Assessment of Cognition in Schizophrenia. Two RCTs (50%) evaluated metformin's effects on total psychopathology and found no significant differences between groups. Adverse events were reported in two RCTs, with inconsistent findings on decreased appetite and diarrhea. Other adverse events and discontinuation rates were comparable between groups.ConclusionPreliminary evidence suggests that metformin may improve neurocognitive function in schizophrenia. However, further large-scale, double-blind, high quality RCTs are warranted to validate these findings. |
| format | Article |
| id | doaj-art-22f2d4486f44405a84b0482fffdf5733 |
| institution | Kabale University |
| issn | 1664-0640 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj-art-22f2d4486f44405a84b0482fffdf57332025-01-20T12:24:21ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402025-01-011510.3389/fpsyt.2024.15401531540153Metformin for neurocognitive dysfunction in schizophrenia: a systematic reviewZhen-Juan Qin0Zhan-Ming Shi1Li-Juan Li2Xin Wei3Hui-Lin Hu4Wei Wei5Zhi-Yuan Xie6Hang-Xi Ji7Yu-Hua Wei8Wei Zheng9Wei Zheng10Department of Psychiatry, The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, ChinaDepartment of Psychiatry, Chongqing Jiangbei Mental Health Center, Chongqing, ChinaDepartment of Neurology, The First Affiliated Hospital of Hainan Medical University, Haikou, ChinaDepartment of Psychiatry, The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, ChinaDepartment of Psychiatry, The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, ChinaDepartment of Psychiatry, The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, ChinaDepartment of Psychiatry, The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, ChinaDepartment of Psychiatry, Chongqing Jiangbei Mental Health Center, Chongqing, ChinaDepartment of Psychiatry, The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, ChinaDepartment of Psychiatry, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, ChinaDepartment of Psychiatry, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Medical University, Guangzhou, ChinaBackgroundThe efficacy and safety of metformin for addressing neurocognitive dysfunction in schizophrenia remain inconclusive. This systematic review evaluates the evidence from randomized controlled trials (RCTs) on the effects of metformin on neurocognitive function in patients with schizophrenia.MethodsA comprehensive search of Chinese databases (WanFang, Chinese Journal Net) and English databases (PubMed, EMBASE, PsycINFO, and Cochrane Library) was conducted to identify RCTs assessing metformin’s impact on neurocognitive outcomes in schizophrenia.ResultsFour RCTs involving 271 patients with schizophrenia were included. Three RCTs (75%) demonstrated significant improvements in neurocognitive function with metformin compared to controls, as assessed by the MATRICS Consensus Cognitive Battery, Repeatable Battery for the Assessment of Neuropsychological Status, and Mini-Mental State Examination, but not the Brief Assessment of Cognition in Schizophrenia. Two RCTs (50%) evaluated metformin's effects on total psychopathology and found no significant differences between groups. Adverse events were reported in two RCTs, with inconsistent findings on decreased appetite and diarrhea. Other adverse events and discontinuation rates were comparable between groups.ConclusionPreliminary evidence suggests that metformin may improve neurocognitive function in schizophrenia. However, further large-scale, double-blind, high quality RCTs are warranted to validate these findings.https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1540153/fullmetforminschizophrenianeurocognitive dysfunctionsystematic reviewefficacy |
| spellingShingle | Zhen-Juan Qin Zhan-Ming Shi Li-Juan Li Xin Wei Hui-Lin Hu Wei Wei Zhi-Yuan Xie Hang-Xi Ji Yu-Hua Wei Wei Zheng Wei Zheng Metformin for neurocognitive dysfunction in schizophrenia: a systematic review Frontiers in Psychiatry metformin schizophrenia neurocognitive dysfunction systematic review efficacy |
| title | Metformin for neurocognitive dysfunction in schizophrenia: a systematic review |
| title_full | Metformin for neurocognitive dysfunction in schizophrenia: a systematic review |
| title_fullStr | Metformin for neurocognitive dysfunction in schizophrenia: a systematic review |
| title_full_unstemmed | Metformin for neurocognitive dysfunction in schizophrenia: a systematic review |
| title_short | Metformin for neurocognitive dysfunction in schizophrenia: a systematic review |
| title_sort | metformin for neurocognitive dysfunction in schizophrenia a systematic review |
| topic | metformin schizophrenia neurocognitive dysfunction systematic review efficacy |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1540153/full |
| work_keys_str_mv | AT zhenjuanqin metforminforneurocognitivedysfunctioninschizophreniaasystematicreview AT zhanmingshi metforminforneurocognitivedysfunctioninschizophreniaasystematicreview AT lijuanli metforminforneurocognitivedysfunctioninschizophreniaasystematicreview AT xinwei metforminforneurocognitivedysfunctioninschizophreniaasystematicreview AT huilinhu metforminforneurocognitivedysfunctioninschizophreniaasystematicreview AT weiwei metforminforneurocognitivedysfunctioninschizophreniaasystematicreview AT zhiyuanxie metforminforneurocognitivedysfunctioninschizophreniaasystematicreview AT hangxiji metforminforneurocognitivedysfunctioninschizophreniaasystematicreview AT yuhuawei metforminforneurocognitivedysfunctioninschizophreniaasystematicreview AT weizheng metforminforneurocognitivedysfunctioninschizophreniaasystematicreview AT weizheng metforminforneurocognitivedysfunctioninschizophreniaasystematicreview |